Novartis’ Radioligand Therapy Gains FDA Nod for Pediatric Patients April 24, 2024 AutoBot News 0 FDA has granted approval for the use of Novartis’ radioligand therapy, Lutathera, to treat pediatric patients with gastroenteropancreatic neuroendocrine tumors.